Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension
- 1 December 2008
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal Of Hypertension
- Vol. 26 (12), 2414-2425
- https://doi.org/10.1097/hjh.0b013e328312c86a
Abstract
Background Levels of marinobufagenin (MBG), an endogenous bufadienolide Na/K-ATPase (NKA) inhibitor, increase in preeclampsia and in NaCl-sensitive hypertension. Methods We tested a 3E9 monoclonal anti-MBG antibody (mAb) for the ability to lower blood pressure (BP) in NaCl-sensitive hypertension and to reverse the preeclampsia-induced inhibition of erythrocyte NKA. Measurements of MBG were performed via immunoassay based on 4G4 anti-MBG mAb. Results In hypertensive Dahl-S rats, intraperitoneal administration of 50 μg/kg 3E9 mAb lowered BP by 32 mmHg and activated the Na/K-pump in the thoracic aorta by 51%. NaCl supplementation of pregnant rats (n = 16) produced a 37 mmHg increase in BP, a 3.5-fold rise in MBG excretion, and a 25% inhibition of the Na/K-pump in the thoracic aorta, compared with pregnant rats on a normal NaCl intake. In eight pregnant hypertensive rats, 3E9 mAb reduced the BP (21 mmHg) and restored the vascular Na/K-pump. In 14 patients with preeclampsia (mean BP, 126 ± 3 mmHg; 26.9 ± 1.4 years; gestational age, 37 ± 0.8 weeks), plasma MBG was increased three-fold and erythrocyte NKA was inhibited compared with that of 12 normotensive pregnant women (mean BP, 71 ± 3 mmHg) (1.5 ± 0.1 vs. 3.1 ± 0.2 μmol Pi/ml/h, respectively; P < 0.01). Ex-vivo 3E9 mAb restored NKA activity in erythrocytes from patients with preeclampsia. As compared with 3E9 mAb, Digibind, an affinity-purified antidigoxin antibody, was less active with respect to lowering BP in both hypertensive models and to restoration of NKA from erythrocytes from patients with preeclampsia. Conclusion Anti-MBG mAbs may be a useful tool in studies of MBG in vitro and in vivo and may offer treatment of preeclampsia.Keywords
This publication has 33 references indexed in Scilit:
- ANP Differentially Modulates Marinobufagenin-Induced Sodium Pump Inhibition in Kidney and AortaHypertension, 2006
- Role of dietary salt in hypertensionLife Sciences, 2006
- Central Role for the Cardiotonic Steroid Marinobufagenin in the Pathogenesis of Experimental Uremic CardiomyopathyHypertension, 2006
- Myocardial PKC β2 and the Sensitivity of Na/K-ATPase to Marinobufagenin Are Reduced by Cicletanine in Dahl HypertensionHypertension, 2003
- Effects of cardiac glycosides on sodium pump expression and function in LLC-PK1 and MDCK cellsKidney International, 2002
- Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesisJournal Of Hypertension, 1996
- Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogsCardiovascular Research, 1996
- Antidigoxin Antibodies in EclampsiaNew England Journal of Medicine, 1988
- Endogenous digitalis-like substance in plasma of volume-expanded dogsNature, 1980
- Purification and characterization ofBiochimica et Biophysica Acta (BBA) - Biomembranes, 1974